Summit Therapeutics Inc. financial data

Symbol
SMMT on Nasdaq
Location
601 Brickell Key Drive, Suite 1000, Miami, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 814 % +173%
Debt-to-equity 15.1 % -88%
Return On Equity -209 % -34.3%
Return On Assets -181 % -163%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 743M shares +2.53%
Common Stock, Shares, Outstanding 743M shares +2.55%
Common Stock, Value, Issued 7.43M USD +2.55%
Weighted Average Number of Shares Outstanding, Basic 743M shares +4.9%
Weighted Average Number of Shares Outstanding, Diluted 743M shares +4.9%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 411M USD +871%
Nonoperating Income (Expense) 15.7M USD -20.5%
Net Income (Loss) Attributable to Parent -746M USD -361%
Earnings Per Share, Basic -1 USD/shares -426%
Earnings Per Share, Diluted -1 USD/shares -426%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 298M USD +948%
Assets, Current 309M USD -5.95%
Property, Plant and Equipment, Net 690K USD +209%
Operating Lease, Right-of-Use Asset 5.55M USD -36.3%
Goodwill 2.04M USD +8.46%
Other Assets, Noncurrent 6.52M USD +247%
Assets 324M USD -5.21%
Accounts Payable, Current 23M USD +588%
Employee-related Liabilities, Current 6.59M USD +35.2%
Accrued Liabilities, Current 26.1M USD +110%
Liabilities, Current 60.3M USD -57%
Operating Lease, Liability, Noncurrent 2.44M USD -51.5%
Other Liabilities, Noncurrent 1.84M USD +15.2%
Liabilities 64.6M USD -56%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.75M USD -10.1%
Retained Earnings (Accumulated Deficit) -1.84B USD -68%
Stockholders' Equity Attributable to Parent 259M USD +33%
Liabilities and Equity 324M USD -5.21%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 743M shares +2.55%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 298M USD +937%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -746M USD -362%
Operating Lease, Liability, Current 3.12M USD -15.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 2.1B USD +63%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 520M USD +1631%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%